Viral Mesothelioma and Asbestos - An Exciting Newbid

Size: px
Start display at page:

Download "Viral Mesothelioma and Asbestos - An Exciting Newbid"

Transcription

1 High prevalence of serum antibodies reacting with simian virus 40 capsid protein mimotopes in patients affected by malignant pleural mesothelioma Elisa Mazzoni a, Alfredo Corallini b, Alfonso Cristaudo c, Angelo Taronna b, Gianfranco Tassi d, Marco Manfrini a, Manola Comar e, Massimo Bovenzi f, Roberto Guaschino g, Francesca Vaniglia h, Corrado Magnani i, Ferruccio Casali j, Giovanni Rezza k, Giuseppe Barbanti-Brodano b, Fernanda Martini a,1,2, and Mauro G. Tognon a,1,2 Sections of a Cell Biology and Molecular Genetics and b Microbiology, University of Ferrara, Ferrara, Italy; c Section of Occupational Medicine, School of Medicine and Surgery, University of Pisa, Pisa, Italy; d Respiratory Diseases Clinic, United Hospitals, Brescia, Italy; e Institute for Maternal and Child Health IRCCS Burlo Garofolo Trieste and f Clinical Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, Trieste, Italy; g Blood Bank, City Hospital of Alessandria, Alessandria, Italy; h Blood Bank, City Hospital of Casale Monferrato, Casale Monferrato, Italy; i Section of Medical Statistics, School of Medicine and Surgery, University of East Piedmont, Novara, Italy; j Clinical Laboratory Analysis, City Hospital of the Republic of San Marino, Republic of San Marino; and k Istituto Superiore di Sanità, Rome, Italy Edited* by George Klein, Karolinska Institute, Stockholm, Sweden, and approved September 19, 2012 (received for review July 31, 2012) Human malignant pleural mesothelioma (MPM) is considered a rare tumor, but recent estimations indicate that one-quarter million people will die of this neoplasm in Europe in the next three decades. The mineral asbestos is considered the main causative agent of this neoplasm. MPM is largely unresponsive to conventional chemotherapy/radiotherapy. In addition to asbestos exposure, genetic predisposition to asbestos carcinogenesis and to simian virus (SV) 40 infection has also been suggested. SV40 is a DNA tumor virus found in some studies to be associated at high prevalence with MPM. SV40 sequences have also been detected, although at a lower prevalence than in MPM, in blood specimens from healthy donors. However, some studies have failed to reveal SV40 footprints in MPM and its association with this neoplasm. These conflicting results indicate the need for further investigations with new approaches. We report on the presence of antibodies in serum samples from patients affected by MPM that specifically react with two different SV40 mimotopes. The two SV40 peptides used in indirect ELISAs correspond to viral capsid proteins. ELISA with the two SV40 mimotopes gave overlapping results. Our data indicate that in serum samples from MPM-affected patients (n = 97), the prevalence of antibodies against SV40 viral capsid protein antigens is significantly higher (26%, P = 0.043) than in the control group (15%) represented by healthy subjects (n = 168) with the same median age (66 y) and sex. Our results suggest that SV40 is associated with a subset of MPM and circulates in humans. antibody neoplasia Human malignant pleural mesothelioma (MPM) is considered a rare tumor, but recent statistical data estimate that one-quarter million people will die of this neoplasm in Europe in the next three decades. MPM is a highly aggressive neoplasm that leads to death in patients in a few months/years from the time of diagnosis (1). The mineral asbestos is the main etiological agent of this neoplasm. Because MPM arises most frequently in workers exposed to asbestos fibers, this neoplasm is considered an occupational disease. The latency period of MPM after exposure to asbestos may reach 40 y or more. In Europe, the MPM peak is expected to occur around (2). There is no standard curative therapy for MPM, which is largely unresponsive to conventional chemotherapy/radiotherapy. It has been shown that 2 10% of asbestos-exposed individuals may develop MPM (3). Because MPM onset occurs decades after asbestos exposure, subjects potentially at risk of developing this malignancy may benefit from early diagnosis (4). At present there is no recognized specific marker for the diagnosis of MPM or for screening of at-risk asbestos-exposed individuals (5). Recent investigations have allowed for the selection of putative markers such as osteopontin (6) and the soluble mesothelin-related protein (7). However, additional studies found that osteopontin is not specific for MPM (8), whereas mesothelin, once considered specific for the MPM epithelial subtype, has been found to be present in serum samples of asbestos workers, too (9). So far, due to a lack of accurate tools and a curative treatment, screening for MPM is currently not recommended. Therefore, the detection of specific markers that can be useful for MPM screening and diagnosis is of paramount importance (10, 11). In addition to asbestos exposure, many investigations have found an association of MPM with oncogenic simian virus (SV) 40 (12, 13). Indeed, many reports have detected SV40 sequences at high prevalence and the expression of its large tumor antigen (Tag) oncoprotein in MPM. A transforming synergistic action between asbestos fibers and SV40 has been proved in human, hamster, and murine mesothelial cells and in animal models (14 16). In MPM patients, genetic predisposition and specific susceptibility to asbestos carcinogenesis and to SV40 infection were also suggested (3, 17 19). Contrasting reports have appeared in the literature on the presence of SV40 footprints in humans and its association with human tumors (20 22). SV40 antibody detection had been attempted in several studies using serologic methods with SV40 virus-like particles (VLPs), but because of high protein homology among the three main polyomaviruses SV40, BKV, and JCV, the results were always affected by some cross-reactivity (23 30). Considerable debate has developed in the scientific community (31). Problems relating to SV40 infection in the human population and its contribution to human cancer were summarized in an evaluation by the Immunization Safety Review Committee established by the Institute of Medicine of the National Academies (32). The committee concluded that the biological evidence is strong that SV40 is a transforming virus, but it is of moderate strength that SV40 exposure from polio vaccine is related to SV40 infection in humans and that SV40 exposure could lead to cancer in humans under natural conditions. The committee also recommended the development of specific and Author contributions: A. Corallini, G.R., G.B.-B., F.M., and M.G.T. designed research; E.M., A. Corallini, A.T., M.M., and F.M. performed research; A. Corallini, A. Cristaudo, G.T., M.M., M.C., M.B., R.G., F.V., C.M., F.C., G.R., F.M., and M.G.T. contributed new reagents/ analytic tools; E.M., A. Corallini, A. Cristaudo, A.T., G.T., M.M., M.C., M.B., R.G., F.V., C.M., F.C., G.R., G.B.-B., F.M., and M.G.T. analyzed data; and G.B.-B., F.M., and M.G.T. wrote the paper. The authors declare no conflict of interest. *This Direct Submission article had a prearranged editor. Freely available online through the PNAS open access option. 1 F.M. and M.G.T. contributed equally to this work. 2 To whom correspondence should be addressed. tgm@unife.it or mrf@unife.it PNAS October 30, 2012 vol. 109 no. 44

2 sensitive serologic tests for SV40 and the use of standardized techniques that should be accepted and shared by all laboratories involved in SV40 detection. A recent investigation reported that an indirect ELISA with SV40-specific synthetic peptides from its viral proteins was successfully used in detecting SV40 antibodies in serum samples from normal individuals, without crossreactivity with other closely related polyomaviruses such as BKV and JCV (33). In this investigation, serum samples from MPM-affected patients and healthy subjects, together with other controls, were analyzed for exposure to SV40 infection by an indirect ELISA using specific mimotopes from SV40 viral capsid proteins (33). Results Serum samples from oncologic patients affected by MPM, together with controls, were analyzed by indirect ELISA for the presence of IgG-class antibodies against SV40 viral capsid protein (VP) mimotopes designated VP1 B and VP2/3 C (33) (Fig. 1). The ELISA indicated that seropositive samples for SV40 VP1 B were also found positive for SV40 VP2/3 C. Conversely, seronegative samples for SV40 VP1 peptide B failed to react with SV40 VP2/3 peptide C. The exceptions were negligible, represented by a few serum samples that were found negative for VP1 B whereas testing positive for VP2/3 C peptide, and vice versa. This difference, between the number of samples found positive for VP1 B and positive for VP2/3 C in the distinct cohorts analyzed, was not statistically significant (P > 0.05) (Tables 1 and 2). In our study, sera were considered SV40-positive when reacting with both VP1 B and VP2/3 C peptides. Fig. 1. Computer-assisted representation of the structure of the SV40 capsid virion refined at 3.1-Å resolution (60), which is publicly available at the Protein Data Bank (PDB) online archive (PDB ID code 1SVA). The macromolecular assembly of the functional form of the molecule is available from the same source. Crystallographic and noncrystallographic transformations, both rotational and translational, are needed to generate the biological assembly. The biological assembly was generated with the RasMol Molecular Graphics Visualization Tool (61, 62) available at The VP1 peptide B (red) was mapped on VP1 capsid proteins, which are present 360 times in the virion. The lack of VP2 and VP3 crystallographic forms did not allow mapping peptide C on these capsid proteins. SV40-positive sera tested by indirect ELISA diluted at 1/20 had a general cutoff, by spectrophotometric reading, in the range of OD (33). Specifically, in serum samples from MPM patients (n = 97), the prevalence of specific SV40 VP antibodies was 26%, whereas in healthy subjects, the control group (n = 168), it was 15%. This difference is statistically significant (P = 0.043). MPM patient and control groups had the same median age (66 y) and sex (they were all males) (Fig. 2 and Table 1). Serologic profiles of serum antibody reactivity to SV40 mimotopes are presented in Fig. 3. The difference in OD mean value of sera from MPM and healthy subjects is not statistically significant (P > 0.05) (Fig. 3). In a second step of our investigation, we verified whether the prevalence of SV40 antibodies determined in serum samples from MPM patients differed from that of workers who had been exposed to asbestos, which is a natural oncogenic mineral with immunosuppressive activity (34, 35). Our study indicated that the prevalence of SV40 VP antibodies detected in workers who had been exposed to asbestos (n = 90) is 9% (Fig. 2 and Table 1). The comparative analysis indicates that the prevalence of SV40-positive sera is higher in MPM patients (26%) compared with that of workers who had been exposed to asbestos. This difference is statistically significant (P = ) (Fig. 2 and Table 1). Interestingly, the reduced prevalence of SV40-positive sera in workers previously exposed to asbestos is very likely due to the immune-suppressive activity of asbestos (34, 35). Thisprevalencewasalsoanalyzedincomparisonwiththatof the control group represented by healthy blood donors (n = 174) with the same median age (54.5 y). The difference in prevalence is not statistically significant (15% vs. 9%, P = 0.19) (Fig. 2 and Table 2). In a third step of our investigation, we analyzed by indirect ELISA the prevalence of SV40 VP mimotopes in a cohort of pregnant women (n = 94). This control group was introduced in this study because pregnancy induces a temporary state of immune depression/immune tolerance (36), and thus would mimic the group of healthy workers exposed to asbestos. The prevalence of SV40 antibodies determined in serum samples from pregnant women was 13%. The comparative analysis indicated that the prevalence of SV40-positive sera is higher in malignant pleural mesothelioma patients (26%) compared with that of pregnant women. This difference is statistically significant (P = 0.036) (Fig. 2 and Table 1). It is worth mentioning that the difference in prevalence of SV40 antibodies between pregnant woman (n = 94, 13%) and healthy blood donors (n = 125, 18%) with the same median age (36 y) is not statistically significant (P = 0.43) (Fig. 2 and Table 2). Discussion In our investigation, serum samples from MPM-affected patients and normal individuals were analyzed for their reactivity to SV40 VP mimotopes using indirect ELISA. Sera from MPM patients reacted against SV40 VP antigens with a higher prevalence (26%) compared with the cohort of controls represented by healthy individuals (15%). The difference is statistically significant. These results indicate that SV40 infection is associated with a subset of MPM and that SV40 antibodies are also present in the adult population, although at a lower prevalence. The high prevalence of SV40 antibodies in serum samples from MPM patients seems to confirm earlier data obtained in investigations carried out with PCR techniques, which indicated a high prevalence of SV40 sequences in MPM DNA (13, 20). Data obtained in normal individuals suggest that natural SV40 infection occurs in human populations with a prevalence lower than that of the ubiquitous JCV and BKV (60 90%) (25). It is possible that SV40 is transmitted through contact in the human environment. Indeed, it has been shown that SV40 is present in urine, stool, tonsil, and blood specimens of carriers, suggesting MEDICAL SCIENCES Mazzoni et al. PNAS October 30, 2012 vol. 109 no

3 Fig. 2. Prevalence of SV40-positive serum samples in patients with malignant pleural mesothelioma, workers exposed to asbestos fibers, and pregnant women. To compare the prevalence of MPM, workers exposed to asbestos fibers, and pregnant women, three different groups of healthy subjects (HS) were chosen with the same median age and sex. Statistical analysis was performed by the χ 2 test with Yates correction. Statistical analyses revealed significant differences in SV40 prevalence between MPM and the relative cohort of healthy subjects (P = 0.043) with the subjects exposed to asbestos fibers (P = ) and with pregnant women (P = 0.036). No statistically significant differences in SV40 seroprevalence were found between the cohorts of pregnant women and subjects exposed to asbestos fibers with their control groups of healthy subjects. *P < 0.05; **P < that different routes of transmission are responsible for SV40 infection (37 45). Our data seem to confirm results obtained by earlier studies in subjects administered SV40-contaminated vaccines by different routes. In these individuals, SV40 was detected/isolated after a number of weeks or days, either in their stool or from their throat depending on oral or nasal spray administration of contaminated vaccines (46, 47). At present, SV40 infection seems to occur independently from early contaminated vaccines. Indeed, many studies have reported SV40 sequences, serum antibodies against SV40, and SV40 isolation/rescue from subjects too young or too old to have been vaccinated with SV40-contaminated vaccines. Altogether, these investigations suggest that SV40 may be contagiously transmitted in the human population either directly by person-to-person contact or indirectly by orofecal and other routes (reviewed in refs. 20 and 31). In healthy individuals (median age 66 y), the overall prevalence of the IgG class of SV40 antibodies is around 15%. It is important to note that SV40 prevalence in human sera from healthy subjects detected by our immunologic study does not differ substantially from that reported by a previous study carried out in the United States using neutralization testing against SV40 infectivity, which is considered the gold standard for measuring the presence of the SV40 antibody (40). In addition, SV40 sequences were detected in earlier studies with a similar prevalence (16%) by PCR assays in healthy blood donors (48). Interestingly, SV40-positive MPM sera had a higher prevalence (26%) than that of workers exposed to asbestos fibers (9%), an immunosuppressive mineral (34, 35), suggesting that asbestos may depress the immune system of these workers. A lower prevalence of SV40-positive sera was also detected in pregnant women (13%). This result is probably due to pregnancy, which induces immune tolerance in women. Serum samples from MPM-affected patients had a prevalence of SV40 antibody that was higher than that of these cohorts of controls, that is, pregnant women and workers exposed to asbestos. The difference was statistically significant. In should be noted that the prevalence of SV40 antibodies determined in asbestos-exposed workers and pregnant women reflects the seroprevalence of the general population. Altogether, this result remarks on the significance of the higher seroprevalence detected in the MPM patient cohort. The onset and progression of MPM, as for other cancers, are associated with specific gene mutations (18, 19). However, the Table 1. Prevalence of serum IgG antibodies reacting with SV40 VP mimotopes in serum samples from MPM-affected patients, healthy subjects, workers exposed to asbestos, and pregnant women Human sera No. of subjects/patients Median age (y) Male (%) No. of positive samples (%) VP B VP C VPs (B-C) Mesothelioma (32) 31 (32) 25 (26) Healthy subjects (18) 28 (17) 25 (15) Workers exposed to asbestos fibers (10) 8 (9) 8 (9) Pregnant women (16) 13 (14) 12 (13) Statistical analysis was performed by the χ 2 test with Yates correction. The different prevalence of SV40 antibodies for the cohort of mesothelioma-affected patients was statistically significant compared with the cohort of healthy individuals (P = 0.043), the cohort of worker exposed to asbestos fibers (P = ), and the cohort of pregnant women (P = 0.036) Mazzoni et al.

4 Fig. 3. Serologic profile of serum antibody reactivity to SV40 mimotopes VP1 B (A) and VP2/3 C (B). Immunologic data are from patients affected by MPM and from healthy subjects. Results are presented as values of OD readings at 405 nm of serum samples diluted at 1:20 detected in an indirect ELISA. In scatter dot plotting, each plot represents the dispersion of OD values to a mean level indicated by the line inside the scatter with SEM for each group of subjects analyzed. The difference in OD mean value was not statistically significant (P > 0.05). agents responsible for the occurrence of mutations/chromosome alterations are poorly understood. Although asbestos is considered the main cause, SV40 may be an additional candidate for causing mutations and chromosome alterations in tumors. SV40 was found to be mutagenic in human cells (20, 31). The viral oncoprotein Tag induces mutations and chromosomal damage characterized by numerical and structural chromosomal alterations such as gaps, breaks, dicentric and ring chromosomes, chromatid exchanges, deletions, duplications, and translocations (20). Alternatively, SV40, although able with its Tag oncogene to bind and inactivate p53- and prb-family proteins, could only be a passenger virus, multiplying better in some transformed cells than in normal cells. Indeed, it has been proved that normal human mesothelial cells as well as other normal human cells are only semipermissive to SV40 multiplication (49 52). The high prevalence of SV40 antibodies in sera from MPM-affected patients is not proof of cause and effect in inducing human tumors by SV40. However, one may postulate that after infecting the host, SV40 may exert its tumorigenic potential when the immune system is impaired. If SV40 is proven to act as a tumor agent in humans, new therapeutic/preventive strategies could be applied with antiviral drugs or vaccines. Materials and Methods Human Samples. Serum samples were collected in different Italian institutions during Anonymously collected sera were coded with indications of age and sex. Informed written consent was obtained from patients and healthy subjects. The project was approved by the County Ethical Committee, Ferrara, Italy. Different cohorts were homogeneously clustered by age, sex, and pathology, if any. Sera from MPM-affected patients (n = 97) were from the universities/hospitals of Brescia, Casale Monferrato, Pisa, and Trieste, whereas sera from asbestos-exposed workers (n = 90) were from the University of Pisa. Sera from pregnant women (n = 94) were from the Istituto Superiore di Sanità, Rome, whereas those from normal individuals (n = 168) and healthy blood donors (n = 299) were from the universities/hospitals of Alessandria, Ferrara, Novara, Republic of San Marino, Rome, and Trieste. Human sera from three different groups of healthy subjects were analyzed: (i) Healthy individuals (n = 168, 66 y median age) were analyzed to compare SV40 seroprevalence with that detected in mesothelioma patients. (ii) Healthy blood donors (n = 125, 36 y median age) was the control group analyzed in comparison with pregnant women. (iii) Healthy blood donors (n = 174, 54.5 y) was the control group analyzed in comparison with the group of workers exposed to asbestos fibers. SV40 Mimotopes. Computer-assisted analyses allowed us to select two specific SV40 peptides from the late viral region by comparing the three capsid proteins VP 1 3 from SV40 with the amino acids of the human BK (BKV) and JC (JCV) polyomaviruses, which are highly homolog to SV40, as well as with other, less homologous, polyomaviruses (33). Previous ELISA results indicated that the two SV40 peptides did not cross-react with the BKV and JCV hyperimmune sera used as controls (33). The two peptides belong to the viral capsid proteins VP1/VP2/VP3 ( The amino acid sequences of the two peptides, named VP1 B and VP2/3 C, are as follows: VP1 B: NH 2 -NPDEHQKGLSKSLAAEKQFTDDSP-COOH VP2/3 C: NH 2 -IQNDIPRLTSQELERRTQRYLRD-COOH VP1 B and VP2/3 C mimotopes were selected because they react specifically in indirect ELISA with the rabbit hyperimmune serum that had been experimentally immunized with SV40 (positive control serum). BKV and JCV hyperimmune sera did not react with VP1 B and VP2/3 C peptides (negative control sera). The amino acid residues of the two specific SV40 VP peptides show low homology to the VPs of BKV and JCV (33). The human peptide hnps, amino acid sequence SFRNGVGTGMKKTSFQRAKS, was used as a negative control peptide (53). The synthetic peptides were synthesized by standard procedures and purchased from UFPeptides. Control Immune Sera. Hyperimmune sera against SV40 and BKV were obtained in rabbits inoculated with purified viral stocks as previously reported (54 56). The serum against JCV was kindly provided by E.O. Major (Laboratory of Molecular Medicine and Neuroscience, National Institute of MEDICAL SCIENCES Table 2. Prevalence of serum IgG antibodies reacting with SV40 VP mimotopes in serum samples from pregnant women, workers exposed to asbestos, and blood donors Human sera No. of subjects/patients Median age (y) Male (%) No. of positive samples (%) VP B VP C VPs (B-C) P value Pregnant women (16) 13 (14) 12 (13) 0.43 Healthy blood donors (21) 27 (22) 22 (18) Workers exposed to asbestos fibers (10) 8 (9) 8 (9) 0.19 Healthy blood donors (19) 36 (21) 27 (15) Statistical analysis was performed by the χ 2 test with Yates correction. No statistically significant differences of SV40 seroprevalence were found between the cohorts of pregnant women and healthy blood donors (P = 0.43) and between the cohorts of subjects exposed to asbestos fibers and healthy blood donors (P = 0.19). Mazzoni et al. PNAS October 30, 2012 vol. 109 no

5 Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD) (57). The immune serum anti-bkv was titered by the hemagglutination inhibition test using human erythrocytes from the 0, Rh + group (55, 58). Anti-SV40 serum was titered by neutralization assay (54, 59). Indirect ELISA. Indirect ELISA was developed and standardized to detect specific antibodies against SV40 in human sera using synthetic peptides (33). Peptide coating. Plates were coated with 5 μg of the selected peptide for each well, diluted in 100 μl of coating buffer (Candor Bioscience). Peptide blocking. Blocking was done with 200 μl per well of blocking solution (Candor Bioscience) at 37 C for 90 min. Primary antibody addition. Different wells were covered with 100 μl containing the following sera: positive control, represented by immune rabbit serum containing anti-sv40 antibodies; negative controls, represented by immune sera anti-bkv and anti-jcv and human serum samples under analysis diluted at 1:20 in low cross-buffer (Candor Bioscience). Each sample was analyzed three times. Secondary antibody addition. The solution contained a goat anti-human IgG heavy chain- and light chain-specific peroxidase conjugate (Calbiochem- Merck) or peroxidase-labeled affinity-purified antibody to human IgM ν (KPL) diluted 1:10,000 in low cross-buffer. Dye treatment and spectrophotometric reading. Samples were treated with 100 μl of 2,2 -azino-bis-3-ethylbenzthiazoline-6-sulfonic acid solution (Sigma- Aldrich) and then read by spectrophotometer (Thermo Electron; model Multiskan EX) at a wavelength of 405 nm. This approach detects color intensity in wells by OD where immunocomplexes are formed. Automatic ELISA. Indirect ELISA was transferred and repeated on the automatic processing system with a DSX instrument (Dynex Technologies). Cutoff determination. The cutoff was determined in each assay by an OD reading of two negative controls added to the SD and multiplied three times (+3 SD). Sera with antibodies against SV40 were considered VP-positive upon reaction with both peptides from the late region. The reproducibility of the results was assessed with three duplicated experiments carried out by independent operators with no data variability. Statistical Analysis. Statistical analyses were performed using Prism software (GraphPad). Data are presented as a percentage of positive samples. Differences among proportions of percentages were calculated by χ 2 with Yates correction testing in contingency tables. Human sera from three different groups of healthy subjects were analyzed: (i) healthy individuals (n = 168, 66 y median age) were analyzed to compare SV40 seroprevalence with that detected in mesothelioma patients; (ii) healthy blood donors (n = 125, 36 y median age) was the control group analyzed in comparison with pregnant women; and (iii) healthy blood donors (n = 174, 54.5 y) was the control group analyzed in comparison with the group of workers exposed to asbestos fibers. The serologic profile of serum antibody reactivity to SV40 mimotopes was statistically analyzed using a Student s unpaired t test. P values less than 0.05 were considered statistically significant. ACKNOWLEDGMENTS. We thank Dr. Eugene O. Major (Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke) for the hyperimmmune serum against JCV. E.M. is a postdoctoral fellow of the Fondazione Umberto Veronesi, Milan. This work was supported, in part, by grants from Fondazione Buzzi UNICEM (Unione Cementieri), Casale Monferrato; ASLEM (Associazione Sanmarinese Leucemie Emopatie Maligne), Repubblica di San Marino; Regione Autonoma Friuli- Venezia Giulia, Assessorato alla Salute e Protezione Sociale, LR 22/2001, 969/ APREV, Trieste; ISS (Istituto Superiore di Sanità), Roma; ISPESL (Istituto superiore per la prevenzione e la sicurezza del lavoro), Roma; Fondazione Cassa di Risparmio di Cento, Cento; Regione Emilia-Romagna, Bologna; and Università di Ferrara, FAR (Fondo di Ateneo per la Ricerca) Projects, Ferrara, Italy. 1. Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366(9483): Peto J, Decarli A, La Vecchia C, Levi F, Negri E (1999) The European mesothelioma epidemic. Br J Cancer 79(3-4): Ismail-Khan R, et al. (2006) Malignant pleural mesothelioma: A comprehensive review. Cancer Contr 13(4): Zucali PA, Giaccone G (2006) Biology and management of malignant pleural mesothelioma. Eur J Cancer 42(16): Zucali PA, et al. (2010) New tricks for old biomarkers: Thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma. Ann Oncol 21(7): Pass HI, et al. (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353(15): Robinson BW, et al. (2003) Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362(9396): Paleari L, et al. (2009) Osteopontin is not a specific marker in malignant pleural mesothelioma. Int J Biol Markers 24(2): Rodríguez Portal JA, et al. (2009) Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: Relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 18(2): Varani K, et al. (2011) A 3 receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-κb pathway. Am J Respir Crit Care Med 183(4): Balatti V, et al. (2011) MicroRNAs dysregulation in human malignant pleural mesothelioma. J Thorac Oncol 6(5): Klein G, Powers A, Croce C (2002) Association of SV40 with human tumors. Oncogene 21(8): Cristaudo A, et al. (2005) SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: A molecular epidemiologic case-control study. Cancer Res 65(8): Pietruska JR, Kane AB (2007) SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells. Cancer Res 67(8): Robinson C, et al. (2006) A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: Malignant transformation is dose dependent. Cancer Res 66(22): Kroczynska B, et al. (2006) Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA 103 (38): Zucali PA, et al. (2011) Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev 37(7): Bott M, et al. (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43(7): Testa JR, et al. (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43(10): Barbanti-Brodano G, et al. (2004) Simian virus 40 infection in humans and association with human diseases: Results and hypotheses. Virology 318(1): López-Ríos F, Illei PB, Rusch V, Ladanyi M (2004) Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 364(9440): Henzi T, et al. (2009) SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis. Am J Pathol 174(6): Ribeiro T, et al. (2010) Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis. Neurol Sci 31(4): Lundstig A, et al. (2005) Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles. J Gen Virol 86(Pt 6): Viscidi RP, et al. (2003) Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol 10(2): Barbanti-Brodano G, Corallini A, Accolla RS, Martini F, Tognon M (2004) Re: Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst 96(10): Carter JJ, et al. (2003) Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst 95(20): Kjaerheim K, et al. (2007) Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples. Int J Cancer 120(11): Kean JM, Rao S, Wang M, Garcea RL (2009) Seroepidemiology of human polyomaviruses. PLoS Pathog 5(3):e Bouvard V, et al.; WHO International Agency for Research on Cancer Monograph Working Group (2012) Carcinogenicity of malaria and of some polyomaviruses. Lancet Oncol 13(4): Martini F, et al. (2007) Simian virus 40 in humans. Infect Agent Cancer 2: Stratton K, Almario DA, McCormick MC, eds (2003) Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer (Natl Acad Press, Washington, DC). 33. Corallini A, et al. (2012) Specific antibodies reacting with simian virus 40 capsid protein mimotopes in serum samples from healthy blood donors. Hum Immunol 73(5): Maeda M, et al. (2010) Dysregulation of the immune system caused by silica and asbestos. J Immunotoxicol 7(4): Tulinska J, et al. (2004) Immunomodulatory effects of mineral fibres in occupationally exposed workers. Mutat Res 553(1-2): Chang D, et al. (1996) Genotypes of human polyomaviruses in urine samples of pregnant women in Taiwan. J Med Virol 48(1): Butel JS, Arrington AS, Wong C, Lednicky JA, Finegold MJ (1999) Molecular evidence of simian virus 40 infections in children. J Infect Dis 180(3): Butel JS, et al. (1999) Evidence of SV40 infections in hospitalized children. Hum Pathol 30(12): Comar M, Zanotta N, Bovenzi M, Campello C (2010) JCV/BKV and SV40 viral load in lymphoid tissues of young immunocompetent children from an area of north-east Italy. J Med Virol 82(7): Jafar S, Rodriguez-Barradas M, Graham DY, Butel JS (1998) Serological evidence of SV40 infections in HIV-infected and HIV-negative adults. J Med Virol 54(4): Mazzoni et al.

6 41. Li RM, et al. (2002) Molecular identification of SV40 infection in human subjects and possible association with kidney disease. J Am Soc Nephrol 13(9): Li RM, et al. (2002) BK virus and SV40 co-infection in polyomavirus nephropathy. Transplantation 74(11): Patel NC, et al. (2008) Detection of polyomavirus SV40 in tonsils from immunocompetent children. J Clin Virol 43(1): Vanchiere JA, White ZS, Butel JS (2005) Detection of BK virus and simian virus 40 in the urine of healthy children. J Med Virol 75(3): Vanchiere JA, et al. (2009) Polyomavirus shedding in the stool of healthy adults. J Clin Microbiol 47(8): Melnick JL, Stinebaugh S (1962) Excretion of vacuolating SV-40 virus (papova virus group) after ingestion as a contaminant of oral poliovaccine. Proc Soc Exp Biol Med 109: Morris JA, Johnson KM, Aulisio CG, Chanock RM, Knight V (1961) Clinical and serologic responses in volunteers given vacuolating virus (SV-40) by respiratory route. Proc Soc Exp Biol Med 108: Pancaldi C, et al. (2009) Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution. J Infect 58(1): Bocchetta M, et al. (2000) Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci USA 97(18): Cacciotti P, et al. (2001) SV40 replication in human mesothelial cells induces HGF/Met receptor activation: A model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA 98(21): Morelli C, Barbisan F, Iaccheri L, Tognon M (2004) Simian virus 40 persistent infection in long-term immortalized human fibroblast cell lines. J Neurovirol 10(4): Mazzoni E, et al. (2012) Simian virus 40 efficiently infects human T lymphocytes and extends their lifespan. Exp Hematol 40(6): Guerrini R, Salvadori S, Rizzi A, Regoli D, Calo G (2010) Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Med Res Rev 30(5): Swetly P, Brodano GB, Knowles B, Koprowski H (1969) Response of simian virus 40- transformed cell lines and cell hybrids to superinfection with simian virus 40 and its deoxyribonucleic acid. J Virol 4(4): Portolani M, Marzocchi A, Barbanti-Brodano G, La Placa M (1974) Prevalence in Italy of antibodies to a new human papovavirus (BK virus). J Med Microbiol 7(4): Maraldi NM, Barbanti-Brodano G, Portolani M, La Placa M (1975) Ultrastructural aspects of BK virus uptake and replication in human fibroblasts. J Gen Virol 27(1): Major EO, et al. (1985) Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci USA 82(4): Neel JV, et al. (1996) Hypothesis: Rogue cell -type chromosomal damage in lymphocytes is associated with infection with the JC human polyoma virus and has implications for oncopenesis. Proc Natl Acad Sci USA 93(7): Barbanti-Brodano G, et al. (2004) Reactivation of infectious simian virus 40 from normal human tissues. J Neurovirol 10(3): Stehle T, Gamblin SJ, Yan Y, Harrison SC (1996) The structure of simian virus 40 refined at 3.1 Å resolution. Structure 4(2): Bernstein HJ (2000) Recent changes to RasMol, recombining the variants. Trends Biochem Sci 25(9): Sayle RA, Milner-White EJ (1995) RASMOL: Biomolecular graphics for all. Trends Biochem Sci 20(9): MEDICAL SCIENCES Mazzoni et al. PNAS October 30, 2012 vol. 109 no

Recent Review Papers on Simian-Virus (SV-40), Asbestos and Mesothelioma. Bibliography

Recent Review Papers on Simian-Virus (SV-40), Asbestos and Mesothelioma. Bibliography Evans AS, Mueller NE (1990) Viruses and cancer causal associations. Ann Epidemiol 1(1): 71-92. Carbone M, Rizzo P & Pass HI (1995) Association of Simian Virus 40 with Rodent and Human Mesotheliomas. DNA

More information

Chapter 18: Applications of Immunology

Chapter 18: Applications of Immunology Chapter 18: Applications of Immunology 1. Vaccinations 2. Monoclonal vs Polyclonal Ab 3. Diagnostic Immunology 1. Vaccinations What is Vaccination? A method of inducing artificial immunity by exposing

More information

Mesothelioma. Mesothelioma and Asbestos 11/21/2009

Mesothelioma. Mesothelioma and Asbestos 11/21/2009 Mesothelioma Michele Carbone, M.D.,PH.D. Director Cancer Research Center of Hawaii Professor and Chairman, Dept. of Pathology J.A. Burns Medical School University of Hawaii Honolulu, HI 96813 Mesotheliomas

More information

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.

More information

Varianti genetiche e interazione gene-asbesto nel mesotelioma pleurico

Varianti genetiche e interazione gene-asbesto nel mesotelioma pleurico Varianti genetiche e interazione gene-asbesto nel mesotelioma pleurico Tunesi Sara, Ferrante Daniela, Mirabelli Dario, Andorno Silvano, Betti Marta, Fiorito Giovanni, Guarrera Simonetta, Casalone Elisabetta,

More information

Molecular Diagnosis of Hepatitis B and Hepatitis D infections

Molecular Diagnosis of Hepatitis B and Hepatitis D infections Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication

More information

KMS-Specialist & Customized Biosimilar Service

KMS-Specialist & Customized Biosimilar Service KMS-Specialist & Customized Biosimilar Service 1. Polyclonal Antibody Development Service KMS offering a variety of Polyclonal Antibody Services to fit your research and production needs. we develop polyclonal

More information

Zika Virus. Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases

Zika Virus. Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases Zika Virus Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases What is the incubation period for Zika virus infection? Unknown but likely to be several

More information

Blood-Based Cancer Diagnostics

Blood-Based Cancer Diagnostics The Biotechnology Education Company Blood-Based Cancer Diagnostics EDVO-Kit 141 Store entire experiment at room temperature. EXPERIMENT OBJECTIVE: The objective of this experiment is to learn and understand

More information

Title: Mapping T cell epitopes in PCV2 capsid protein - NPB #08-159. Date Submitted: 12-11-09

Title: Mapping T cell epitopes in PCV2 capsid protein - NPB #08-159. Date Submitted: 12-11-09 Title: Mapping T cell epitopes in PCV2 capsid protein - NPB #08-159 Investigator: Institution: Carol Wyatt Kansas State University Date Submitted: 12-11-09 Industry summary: Effective circovirus vaccines

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies

More information

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes

More information

7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology)

7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology) 7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology) Students should fulfill a total of 44 credit hours: 1- Compulsory courses: 14 credit hours. 1504801, 1504802, 1504803,

More information

Antibody Function & Structure

Antibody Function & Structure Antibody Function & Structure Specifically bind to antigens in both the recognition phase (cellular receptors) and during the effector phase (synthesis and secretion) of humoral immunity Serology: the

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or

More information

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University

More information

Diagnosis of HIV-1 Infection. Estelle Piwowar-Manning HPTN Central Laboratory The Johns Hopkins University

Diagnosis of HIV-1 Infection. Estelle Piwowar-Manning HPTN Central Laboratory The Johns Hopkins University Diagnosis of HIV-1 Infection Estelle Piwowar-Manning HPTN Central Laboratory The Johns Hopkins University Tests Used to Diagnose HIV-1 Infection HIV antibody (today s topic) HIV p24 antigen HIV DNA HIV

More information

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

Overview of Phase 1 Oncology Trials of Biologic Therapeutics Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of

More information

Topic: Serological reactions: the purpose and a principle of reactions. Agglutination test. Precipitation test. CFT, IFT, ELISA, RIA.

Topic: Serological reactions: the purpose and a principle of reactions. Agglutination test. Precipitation test. CFT, IFT, ELISA, RIA. Topic: Serological reactions: the purpose and a principle of reactions. Agglutination test. Precipitation test. CFT, IFT, ELISA, RIA. Serology is the study and use of immunological tests to diagnose and

More information

New HLA class I epitopes defined by murine monoclonal antibodies

New HLA class I epitopes defined by murine monoclonal antibodies Human Immunology 71 (2010) 456 461 Contents lists available at ScienceDirect New HLA class I epitopes defined by murine monoclonal antibodies Nadim El-Awar a, *, Paul I. Terasaki b, Anh Nguyen a, Mamie

More information

CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma

CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma Occult HBV Infection: Assessment and Clinical Significance D. Lorne Tyrrell Director, Li Ka Shing Institute of Virology University of Alberta

More information

Gene Therapy and Genetic Counseling. Chapter 20

Gene Therapy and Genetic Counseling. Chapter 20 Gene Therapy and Genetic Counseling Chapter 20 What is Gene Therapy? Treating a disease by replacing, manipulating or supplementing a gene The act of changing an individual s DNA sequence to fix a non-functional

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

Custom Antibody Services

Custom Antibody Services prosci-inc.com Custom Antibody Services High Performance Antibodies and More Broad Antibody Catalog Extensive Antibody Services CUSTOM ANTIBODY SERVICES Established in 1998, ProSci Incorporated is a leading

More information

JIANGSU CARTMAY INDUSTRIAL CO.,LTD www.labfurniture.asia mail: info@labfurniture.asia

JIANGSU CARTMAY INDUSTRIAL CO.,LTD www.labfurniture.asia mail: info@labfurniture.asia The basic layout, the main functions and instrumentation concept of micro Inspection Division laboratory, 1, Virology Laboratory 1. Functions: for the city to monitor the prevalence of HIV disease, dealing

More information

Parvovirus B19 Infection in Pregnancy

Parvovirus B19 Infection in Pregnancy Parvovirus B19 Infection in Pregnancy Information Pack Parvovirus B19 Infection in Pregnancy Information Booklet CONTENTS: THE VIRUS page 3 CLINICAL MANIFESTATIONS page 6 DIAGNOSIS page 8 PATIENT MANAGEMENT

More information

LAB 14 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)

LAB 14 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) STUDENT GUIDE LAB 14 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) GOAL The goal of this laboratory lesson is to explain the concepts and technique of enzyme linked immunosorbent assay (ELISA). OBJECTIVES

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

4A. Types of Laboratory Tests Available and Specimens Required. Three main types of laboratory tests are used for diagnosing CHIK: virus

4A. Types of Laboratory Tests Available and Specimens Required. Three main types of laboratory tests are used for diagnosing CHIK: virus 4. LABORATORY 4A. Types of Laboratory Tests Available and Specimens Required Three main types of laboratory tests are used for diagnosing CHIK: virus isolation, reverse transcriptase-polymerase chain reaction

More information

Algorithm for detecting Zika virus (ZIKV) 1

Algorithm for detecting Zika virus (ZIKV) 1 Algorithm for detecting Zika virus (ZIKV) 1 This algorithm is addressed to laboratories with established capacity (molecular, antigenic and/or serological) to detect dengue (DENV), Zika (ZIKV) 2, and chikungunya

More information

High Resolution Epitope Mapping of Human Autoimmune Sera against Antigens CENPA and KDM6B. PEPperPRINT GmbH Heidelberg, 06/2014

High Resolution Epitope Mapping of Human Autoimmune Sera against Antigens CENPA and KDM6B. PEPperPRINT GmbH Heidelberg, 06/2014 High Resolution Epitope Mapping of Human Autoimmune Sera against Antigens CENPA and KDM6B PEPperPRINT GmbH Heidelberg, 06/2014 Introduction This report describes the epitope mapping of autoimmune sera

More information

Chapter 3. Immunity and how vaccines work

Chapter 3. Immunity and how vaccines work Chapter 3 Immunity and how vaccines work 3.1 Objectives: To understand and describe the immune system and how vaccines produce immunity To understand the differences between Passive and Active immunity

More information

QuickTiter Hepatitis B Surface Antigen (HBsAg) ELISA Kit

QuickTiter Hepatitis B Surface Antigen (HBsAg) ELISA Kit Product Manual QuickTiter Hepatitis B Surface Antigen (HBsAg) ELISA Kit Catalog Numbers VPK-5004 VPK-5004-5 96 assays 5 x 96 assays FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction

More information

ELISA BIO 110 Lab 1. Immunity and Disease

ELISA BIO 110 Lab 1. Immunity and Disease ELISA BIO 110 Lab 1 Immunity and Disease Introduction The principal role of the mammalian immune response is to contain infectious disease agents. This response is mediated by several cellular and molecular

More information

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research

More information

Influenza antibody profiling by protein microarray. Marion Koopmans, Professor of public health virology Head Viroscience department

Influenza antibody profiling by protein microarray. Marion Koopmans, Professor of public health virology Head Viroscience department Influenza antibody profiling by protein microarray Marion Koopmans, Professor of public health virology Head Viroscience department Influenza serology applications 1. Evaluation of vaccine response (functional

More information

EMA and Progressive Multifocal Leukoencephalopathy.

EMA and Progressive Multifocal Leukoencephalopathy. EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency of

More information

Basics of Immunology

Basics of Immunology Basics of Immunology 2 Basics of Immunology What is the immune system? Biological mechanism for identifying and destroying pathogens within a larger organism. Pathogens: agents that cause disease Bacteria,

More information

When B Cells Go Bad: Infection, Inflammation and Chronic B Cell Stimulation

When B Cells Go Bad: Infection, Inflammation and Chronic B Cell Stimulation When B Cells Go Bad: Infection, Inflammation and Chronic B Cell Stimulation Karen S. Anderson MD PhD Associate Professor, Biodesign Institute Arizona State University Mayo Clinic Arizona Conflicts of Interest

More information

HuCAL Custom Monoclonal Antibodies

HuCAL Custom Monoclonal Antibodies HuCAL Custom Monoclonal HuCAL Custom Monoclonal Antibodies Highly Specific, Recombinant Antibodies in 8 Weeks Highly Specific Monoclonal Antibodies in Just 8 Weeks HuCAL PLATINUM (Human Combinatorial Antibody

More information

Biopharmaceutical Process Evaluated for Viral Clearance

Biopharmaceutical Process Evaluated for Viral Clearance Authored by S. Steve Zhou, Ph.D. Microbac Laboratories, Inc., Microbiotest Division The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate

More information

Antigens & Antibodies II. Polyclonal antibodies vs Monoclonal antibodies

Antigens & Antibodies II. Polyclonal antibodies vs Monoclonal antibodies A Brief Review of Antibody Structure A Brief Review of Antibody Structure The basic antibody is a dimer of dimer (2 heavy chain-light chain pairs) composed of repeats of a single structural unit known

More information

Ariela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae

Ariela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae Ariela Benigni Biol.Sci.D., Ph.D. Curriculum Vitae Personal Data Name: Date and place of birth: Citizenship: E-mail: Ariela Benigni December 16, 1955 - Bergamo, Italy Italian ariela.benigni@marionegri.it

More information

Post-operative intrapleural chemotherapy for mesothelioma

Post-operative intrapleural chemotherapy for mesothelioma Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy

More information

Analysis of the adaptive immune response to West Nile virus

Analysis of the adaptive immune response to West Nile virus Analysis of the adaptive immune response to West Nile virus Jonathan Bramson (PI) Robin Parsons Alina Lelic Galina Denisova Lesley Latham Carole Evelegh Dmitri Denisov Strategy for characterizing T cell

More information

Plaintiffs Experts Latest Pathological Theories

Plaintiffs Experts Latest Pathological Theories Plaintiffs Experts Latest Pathological Theories Kurt B. Gerstner Campbell Campbell Edwards & Conroy, P.C. One Constitution Center Boston, MA 02129 (617) 241-3086 kgerstner@campbell-trial-lawyers.com Kurt

More information

Rheumatoid arthritis: an overview. Christine Pham MD

Rheumatoid arthritis: an overview. Christine Pham MD Rheumatoid arthritis: an overview Christine Pham MD RA prevalence Chronic inflammatory disease affecting approximately 0.5 1% of the general population Prevalence is higher in North America (approaching

More information

Custom Antibodies & Recombinant Proteins

Custom Antibodies & Recombinant Proteins Custom Antibodies & Recombinant Proteins INTRODUCTION Custom services to meet your research and development requirements Improvements in health, medicine and diagnostics over the past century can be largely

More information

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line i 1 INTRODUCTION 1.1 Human Hepatitis B virus (HBV) 1 1.1.1 Pathogenesis of Hepatitis B 1 1.1.2 Genome organization of HBV 3 1.1.3 Structure of HBV virion 5 1.1.4 HBV life cycle 5 1.1.5 Experimental models

More information

Interest in any of the products, request or order them at Bio-Connect Diagnostics.

Interest in any of the products, request or order them at Bio-Connect Diagnostics. MESOMARK, Brochure Interest in any of the products, request or order them at Bio-Connect Diagnostics. Bio-Connect Diagnostics B.V. T NL +31 () 3 T BE +3 () 5 1 53 Begonialaan 3a F NL +31 () 3 1 F BE +3

More information

The Need for a PARP in vivo Pharmacodynamic Assay

The Need for a PARP in vivo Pharmacodynamic Assay The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D., Chief Scientific Officer, Trevigen, Inc., Gaithersburg, MD For further infomation, please contact: William Booth, Ph.D. Tel: +44 (0)1235

More information

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015 The role of IBV proteins in protection: cellular immune responses COST meeting WG2 + WG3 Budapest, Hungary, 2015 1 Presentation include: Laboratory results Literature summary Role of T cells in response

More information

Griffith University - Case for Support. Mesothelioma Research Program

Griffith University - Case for Support. Mesothelioma Research Program Griffith University - Case for Support Mesothelioma Research Program Professor Lyn Griffiths Director, Dean, Research and Director, Genomics Research Centre (GHI) Established in 2007. Integrated health

More information

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates

More information

The Basics of Drug Resistance:

The Basics of Drug Resistance: CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?

More information

Viral Hepatitis Case Report

Viral Hepatitis Case Report Page 1 of 9 Viral Hepatitis Case Report Perinatal Hepatitis B Virus Infection Michigan Department of Community Health Communicable Disease Division Investigation Information Investigation ID Onset Date

More information

ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES

ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES DESCRIPTION OF GRANT MECHANISM The Alliance for Lupus Research (ALR) is an independent,

More information

Hereditary Ovarian cancer: BRCA1 and BRCA2. Karen H. Lu MD September 22, 2013

Hereditary Ovarian cancer: BRCA1 and BRCA2. Karen H. Lu MD September 22, 2013 Hereditary Ovarian cancer: BRCA1 and BRCA2 Karen H. Lu MD September 22, 2013 Outline Hereditary Breast and Ovarian Cancer (HBOC) BRCA1/2 genes How to identify What it means to you What it means to your

More information

RSV F Recombinant Nanoparticle Vaccine: Summary of Clinical Data

RSV F Recombinant Nanoparticle Vaccine: Summary of Clinical Data RSV F Recombinant Nanoparticle Vaccine: Summary of Clinical Data Gregory M. Glenn M.D., SVP R&D Project Lead for RSV 9 th International Respiratory Syncytial Virus Symposium Cape Town, South Africa November

More information

Reconsideration Code 86386. Reconsideration Code Description Nuclear Matrix Protein 22 (NMP22), qualitative

Reconsideration Code 86386. Reconsideration Code Description Nuclear Matrix Protein 22 (NMP22), qualitative Calendar Year 2013 Centers for Medicare and Medicaid Services (CMS) New and Reconsidered Clinical Laboratory Fee Schedule (CLFS) Test Codes And Final Payment Determinations Reconsideration Code 86386 Reconsideration

More information

1) Siderophores are bacterial proteins that compete with animal A) Antibodies. B) Red blood cells. C) Transferrin. D) White blood cells. E) Receptors.

1) Siderophores are bacterial proteins that compete with animal A) Antibodies. B) Red blood cells. C) Transferrin. D) White blood cells. E) Receptors. Prof. Lester s BIOL 210 Practice Exam 4 (There is no answer key. Please do not email or ask me for answers.) Chapters 15, 16, 17, 19, HIV/AIDS, TB, Quorum Sensing 1) Siderophores are bacterial proteins

More information

Basic Immunologic Procedures. Complex Serological Tests

Basic Immunologic Procedures. Complex Serological Tests Basic Immunologic Procedures Complex Serological Tests Amal Alghamdi 2014-2015 1 Classification of antigen-antibody interactions: 1. Primary serological tests: (Marker techniques) e.g. Enzyme linked immuonosorben

More information

QuickTiter FeLV Core Antigen ELISA Kit (FeLV p27)

QuickTiter FeLV Core Antigen ELISA Kit (FeLV p27) Product Manual QuickTiter FeLV Core Antigen ELISA Kit (FeLV p27) Catalog Numbers VPK-155 96 wells FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Feline leukemia virus (FeLV) is

More information

How Does a Doctor Test for AIDS?

How Does a Doctor Test for AIDS? Edvo-Kit #S-70 How Does a Doctor Test for AIDS? S-70 Experiment Objective: The Human Immunodefi ciency Virus (HIV) is an infectious agent that causes Acquired Immunodefi ciency Syndrome (AIDS) in humans.

More information

HuCAL Custom Monoclonal Antibodies

HuCAL Custom Monoclonal Antibodies HuCAL Custom Monoclonal Antibodies Highly Specific Monoclonal Antibodies in just 8 Weeks PROVEN, HIGHLY SPECIFIC, HIGH AFFINITY ANTIBODIES IN 8 WEEKS WITHOUT HuCAL PLATINUM IMMUNIZATION (Human Combinatorial

More information

Breast cancer and the role of low penetrance alleles: a focus on ATM gene

Breast cancer and the role of low penetrance alleles: a focus on ATM gene Modena 18-19 novembre 2010 Breast cancer and the role of low penetrance alleles: a focus on ATM gene Dr. Laura La Paglia Breast Cancer genetic Other BC susceptibility genes TP53 PTEN STK11 CHEK2 BRCA1

More information

IKDT Laboratory. IKDT as Service Lab (CRO) for Molecular Diagnostics

IKDT Laboratory. IKDT as Service Lab (CRO) for Molecular Diagnostics Page 1 IKDT Laboratory IKDT as Service Lab (CRO) for Molecular Diagnostics IKDT lab offer is complete diagnostic service to all external customers. We could perform as well single procedures or complex

More information

HIV and Autoimmune Disease - The Cure Research

HIV and Autoimmune Disease - The Cure Research 1. Purpose of the study- This is a cross-sectional study that analyzes the sera of subjects in order to answer two clinical questions. First, we will assay the antibody profiles of subjects with autoimmune

More information

MUTATION, DNA REPAIR AND CANCER

MUTATION, DNA REPAIR AND CANCER MUTATION, DNA REPAIR AND CANCER 1 Mutation A heritable change in the genetic material Essential to the continuity of life Source of variation for natural selection New mutations are more likely to be harmful

More information

Seattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.

Seattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion. Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case

More information

Immunity and how vaccines work

Immunity and how vaccines work 1 Introduction Immunity is the ability of the human body to protect itself from infectious disease. The defence mechanisms of the body are complex and include innate (non-specific, non-adaptive) mechanisms

More information

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine January 27, 2009 Dear Professors (representative) of departments, Subject:

More information

OCCUPATIONAL LUNG CANCER

OCCUPATIONAL LUNG CANCER OCCUPATIONAL LUNG CANCER Anwar Jusuf, Agus Dwi Susanto Department of Pulmonology & Respiratory Medicine, Faculty of Medicine University Of Indonesia - Persahabatan Hospital-Jakarta INTRODUCTION Occupational

More information

UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and

UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE

More information

B Cells and Antibodies

B Cells and Antibodies B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production

More information

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1 1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY

More information

Mesothelioma among shipyard workers in Monfalcone, Italy

Mesothelioma among shipyard workers in Monfalcone, Italy Original Article Mesothelioma among shipyard workers in Monfalcone, Italy Abstract Background: The high mesothelioma incidence in Monfalcone, Italy, is mainly attributable to shipbuilding activity. Mesothelioma

More information

Some Immunological Test. Presented by Alaa Faeiz Ashwaaq Dyaa Aseel Abd AL-Razaq Supervised by D.Feras

Some Immunological Test. Presented by Alaa Faeiz Ashwaaq Dyaa Aseel Abd AL-Razaq Supervised by D.Feras Some Immunological Test Presented by Alaa Faeiz Ashwaaq Dyaa Aseel Abd AL-Razaq Supervised by D.Feras Alaa Faeiz Antigen -Antibody Reactions. Antigen antibody reactions are performed to determine the presence

More information

Autoimmunity and immunemediated. FOCiS. Lecture outline

Autoimmunity and immunemediated. FOCiS. Lecture outline 1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic

More information

Natalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia

Natalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia Pathogenesis of Dengue Natalia Taborda Vanegas Doc. Sci. Student Immunovirology Group Universidad de Antioquia Infection process Epidermis keratinocytes Dermis Archives of Medical Research 36 (2005) 425

More information

Influence of Fiber Type, Size, and Number in Human Disease: Conclusions from Fiber Burden Analysis

Influence of Fiber Type, Size, and Number in Human Disease: Conclusions from Fiber Burden Analysis Influence of Fiber Type, Size, and Number in Human Disease: Conclusions from Fiber Burden Analysis Andrew Churg, MD Department of Pathology University of British Columbia Vancouver, BC, Canada Techniques,

More information

Nutrition and Toxicants in Autoimmune Disease: Implications for Prevention and Treatment

Nutrition and Toxicants in Autoimmune Disease: Implications for Prevention and Treatment Nutrition and Toxicants in Autoimmune Disease: Implications for Prevention and Treatment Collaborative on Health and the Environment June 17, 2014 Ted Schettler MD, MPH 1 Autoimmune diseases Autoimmunity

More information

Update of the scientific evidence on asbestos and cancer. Kurt Straif, MD MPH PhD. The IARC Monographs

Update of the scientific evidence on asbestos and cancer. Kurt Straif, MD MPH PhD. The IARC Monographs Update of the scientific evidence on asbestos and cancer Kurt Straif, MD MPH PhD International Agency for Research on Cancer Lyon, France World Health Organisation Asturias, 17 March 2011 The IARC Monographs

More information

Hepatitis C Glossary of Terms

Hepatitis C Glossary of Terms Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune

More information

Virological Methods. Flint et al. Principles of Virology (ASM), Chapter 2

Virological Methods. Flint et al. Principles of Virology (ASM), Chapter 2 Virological Methods Flint et al. Principles of Virology (ASM), Chapter 2 Overview The most commonly used laboratory methods for the detection of viruses and virus components in biological samples can be

More information

SUMMARY AND EXPLANATION OF THE TEST

SUMMARY AND EXPLANATION OF THE TEST DxSelect (English) REF EL1950 Rev. C Enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of human antibodies to JC virus For in vitro diagnostic use INTENDED USE The Focus Diagnostics

More information

Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs

Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs Provisional Translation (as of January 27, 2014)* November 15, 2013 Pharmaceuticals and Bio-products Subcommittees, Science Board Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer

More information

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction

More information

CHAPTER 8 IMMUNOLOGICAL IMPLICATIONS OF PEPTIDE CARBOHYDRATE MIMICRY

CHAPTER 8 IMMUNOLOGICAL IMPLICATIONS OF PEPTIDE CARBOHYDRATE MIMICRY CHAPTER 8 IMMUNOLOGICAL IMPLICATIONS OF PEPTIDE CARBOHYDRATE MIMICRY Immunological Implications of Peptide-Carbohydrate Mimicry 8.1 Introduction The two chemically dissimilar molecules, a peptide (12mer)

More information

Diagnostic Testing and Strategies for BVDV

Diagnostic Testing and Strategies for BVDV Diagnostic Testing and Strategies for BVDV Dan Grooms Dept. of Large Animal Clinical Sciences College of Veterinary Medicine Introduction Clinical diseases in cattle resulting from infection with bovine

More information

Pathologist s Discussion of Plaintiffs Latest Theories

Pathologist s Discussion of Plaintiffs Latest Theories Pathologist s Discussion of Plaintiffs Latest Theories Mary Beth Beasley, MD Mt. Sinai Medical Center Annenberg Building 15th Floor Room 50 1468 Madison Avenue New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com

More information

How To Kill Jesuva

How To Kill Jesuva Summary of Key Points WHO Position Paper on Vaccines against Japanese Encephalitis (JE) February 2015 1 Background l Japanese Encephalitis Virus (JEV) is the leading cause of viral encephalitis in Asia

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

M110.726 The Nucleus M110.727 The Cytoskeleton M340.703 Cell Structure and Dynamics

M110.726 The Nucleus M110.727 The Cytoskeleton M340.703 Cell Structure and Dynamics of Biochemistry and Molecular Biology 1. Master the knowledge base of current biochemistry, molecular biology, and cellular physiology Describe current knowledge in metabolic transformations conducted

More information

Measles (Rubeola) IgM ELISA Catalog No. CB40-101-325099 (96 Tests)

Measles (Rubeola) IgM ELISA Catalog No. CB40-101-325099 (96 Tests) For Research Use Only. Not for use in Diagnostic Procedures. INTENDED USE Measles test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in

More information

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,

More information

Non-clinical development of biologics

Non-clinical development of biologics Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service

More information

Pharmacology skills for drug discovery. Why is pharmacology important?

Pharmacology skills for drug discovery. Why is pharmacology important? skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th

More information

Name Date Class. This section explains what kinds of organisms cause infectious disease and how infectious diseases are spread.

Name Date Class. This section explains what kinds of organisms cause infectious disease and how infectious diseases are spread. Fighting Disease Name Date Class Infectious Disease This section explains what kinds of organisms cause infectious disease and how infectious diseases are spread. Use Target Reading Skills Before you read,

More information

LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH

LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH FUNDING OPPORTUNITY DESCRIPTION 2016 REQUEST FOR APPLICATION (RFA) Lung Cancer Foundation of America (LCFA) and the International

More information